Lisa A. Carey, MD, of the University of North Carolina, and Julie Gralow, MD, of the University of Washington, discuss the most important data presented this year on treating breast malignancies (Abstracts LBA1, 500, and 507).
Antonio Palumbo, MD, of the University of Torino, discusses this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).
Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.
Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).
